Oncotarget

Research Papers:

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

Michael Schmitt, Angela G. Hückelhoven, Michael Hundemer, Anita Schmitt, Susanne Lipp, Martina Emde, Hans Salwender, Mathias Hänel, Katja Weisel, Uta Bertsch, Jan Dürig, Anthony D. Ho, Igor Wolfgang Blau, Hartmut Goldschmidt, Anja Seckinger and Dirk Hose _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:84847-84862. https://doi.org/10.18632/oncotarget.11215

Metrics: PDF 2328 views  |   HTML 3441 views  |   ?  


Abstract

Michael Schmitt1,*, Angela G. Hückelhoven1,*, Michael Hundemer1, Anita Schmitt1, Susanne Lipp1, Martina Emde1, Hans Salwender2, Mathias Hänel3, Katja Weisel4, Uta Bertsch1, Jan Dürig5, Anthony D. Ho1, Igor Wolfgang Blau6, Hartmut Goldschmidt1,7, Anja Seckinger1 and Dirk Hose1

1Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany

2Department of Internal Medicine II, Asklepios Klinik Altona, Hamburg, Germany

3Department of Internal Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany

4Department of Hematology, Oncology and Immunology, University of Tübingen, Tübingen, Germany

5Department of Hematology, University Hospital Essen, Essen, Germany

6Medical Clinic III Hematology and Oncology, Charité University Medicine Berlin, Berlin, Germany

7Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany

*These authors contributed equally to this work

Correspondence to:

Dirk Hose, email: [email protected]

Keywords: tumor associated antigens, T cells, immunogenicity, multiple myeloma, RNA-sequencing

Received: May 20, 2016     Accepted: July 13, 2016     Published: August 11, 2016

ABSTRACT

Background: Raising T-cell response against antigens either expressed on normal and malignant plasma cells (e.g. HM1.24) or aberrantly on myeloma cells only (e.g. cancer testis antigens, CTA) by vaccination is a potential treatment approach for multiple myeloma.

Results: Expression by GEP is found for HM1.24 in all, HMMR in 318/458 (69.4%), MAGE-A3 in 209/458 (45.6%), NY-ESO-1/2 in 40/458 (8.7%), and WT-1 in 4/458 (0.8%) of samples with the pattern being confirmed by RNA-sequencing. T-cell-activation is found in 9/26 (34.6%) of patient samples, i.e. against HM1.24 (4/24), RHAMM-R3 (3/26), RHAMM1-8 (2/14), WT-1 (1/11), NY-ESO-1/2 (1/9), and MAGE-A3 (2/8). In 7/19 T-cell activation responses, myeloma cells lack respective antigen-expression. Expression of MAGE-A3, HMMR and NY-ESO-1/2 is associated with adverse survival.

Experimental design: We assessed expression of HM1.24 and the CTAs MAGE-A3, NY-ESO-1/2, WT-1 and HMMR in CD138-purified myeloma cell samples of previously untreated myeloma patients in the GMMG-MM5 multicenter-trial by gene expression profiling (GEP; n = 458) and RNA-sequencing (n = 152) as potential population regarding vaccination trials. We then validated the feasibility to generate T-cell responses (n = 72) against these antigens by IFN-γ EliSpot-assay (n = 26) related to antigen expression (n = 22). Lastly, we assessed survival impact of antigen expression in an independent cohort of 247 patients treated by high-dose therapy and autologous stem cell transplantation.

Conclusions: As T-cell responses can only be raised in a subfraction of patients despite antigen expression, and the number of responses increases with more antigens used, vaccination strategies should assess patients’ antigen expression and use a “cocktail” of peptide vaccines.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11215